SinoMab BioScience Limited - Laporan Laba Rugi (TTM)

SinoMab BioScience Limited
HK ˙ SEHK ˙ HK0000544194
HK$ 1.78 ↓ -0.11 (-5.82%)
2025-09-12
BAHAGING PRESYO
Laporan Laba Rugi (TTM)

Laporan Laba Rugi SinoMab BioScience Limited menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 6 13 13 13 20 27 30 34 19 4 5 5 3 1 3 2 1 2 1 0
Change (%) 100.00 0.00 0.00 54.46 35.26 13.99 12.27 -44.09 -78.86 12.55 11.15 -36.47 -57.40 134.29 -37.34 -74.98 303.99 -50.00 -100.00
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 0 1 1 1 1 1 1 1 1 0
Change (%) 100.00 0.00 0.00 28.63 22.26 0.00 0.00 -50.00 -100.00
% of Revenue 10.39 18.70 29.43 69.08 37.93 74.00 295.71 73.20 73.20
Gross Operating Profit 6 13 13 13 20 27 30 34 19 4 4 4 2 0 2 1 -1 1 0 0
Change (%) 100.00 0.00 0.00 54.46 35.26 13.99 12.27 -44.09 -78.86 0.86 0.85 -44.85 -81.34 370.38 -73.75 -288.39 -155.32 -50.00 -100.00
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 89.61 81.30 70.57 30.92 62.07 26.00 -195.71 26.80 26.80
SG&A 86 72 63 55 94 133 134 134 108 83 91 99 98 98 90 82 75 68 62 57
Change (%) -16.06 -11.92 -13.53 71.62 41.73 0.37 0.37 -19.27 -23.87 9.90 9.01 -0.67 -0.68 -8.19 -8.92 -8.52 -9.31 -7.73 -8.38
% of Revenue 1,344.55 564.34 497.07 429.79 477.56 500.43 440.65 393.94 568.81 2,048.39 2,000.14 1,961.58 3,066.89 7,151.28 2,802.30 4,072.85 14,888.93 3,342.35 6,167.87
R&D 166 103 124 146 172 199 195 191 186 180 173 165 150 135 130 124 109 95 84 72
Change (%) -37.86 20.39 16.94 18.39 15.53 -1.97 -2.01 -2.85 -2.93 -4.26 -4.45 -8.96 -9.85 -4.33 -4.52 -11.70 -13.25 -11.76 -13.33
% of Revenue 2,607.99 810.36 975.59 1,140.82 874.45 746.94 642.37 560.66 974.23 4,473.41 3,805.15 3,270.96 4,687.10 9,920.07 4,051.02 6,172.36 21,779.36 4,676.85 8,253.26
OpEx 252 175 188 200 266 333 329 326 294 263 264 265 249 234 220 207 185 164 147 130
Change (%) -30.44 7.13 6.65 32.96 24.79 -1.03 -1.04 -9.63 -10.65 0.36 0.36 -5.83 -6.20 -5.81 -6.16 -10.36 -11.56 -10.44 -11.66
% of Revenue 3,952.55 1,374.70 1,472.65 1,570.60 1,352.01 1,247.38 1,083.02 954.59 1,543.04 6,521.80 5,815.68 5,251.23 7,783.41 17,140.44 6,891.24 10,319.21 36,964.01 8,092.40 14,494.32
Operating Income -246 -163 -175 -188 -247 -306 -299 -292 -275 -259 -259 -260 -246 -233 -217 -205 -185 -162 -146 -130
Change (%) -33.83 7.68 7.14 31.50 23.95 -2.34 -2.40 -5.59 -5.92 0.17 0.17 -5.24 -5.53 -6.63 -5.71 -9.73 -12.41 -9.95 -11.05
% of Revenue -3,852.55 -1,274.70 -1,372.65 -1,470.60 -1,252.01 -1,147.38 -983.02 -854.59 -1,443.04 -6,421.80 -5,715.68 -5,151.23 -7,683.41 -17,040.44 -6,791.24 -10,219.21 -36,864.01 -7,992.40 -14,394.32
Interest Expense -2 -2 -3 -3 -5 -6 -6 -5 -5 -5 -5 -6 -6 -7 -7 -7 -8 -9 -9 -8
Change (%) -2.84 20.18 16.79 35.83 26.38 -3.08 -3.18 -4.58 -4.80 10.70 9.67 4.65 4.44 0.65 0.64 14.93 12.99 -1.71 -1.74
% of Revenue -38.97 -18.93 -22.75 -26.58 -23.37 -21.84 -18.57 -16.01 -27.33 -123.07 -121.04 -119.43 -196.72 -482.34 -207.21 -332.78 -1,528.41 -427.49 -840.33
Net Income -217 -123 -139 -156 -222 -288 -303 -318 -301 -284 -279 -274 -259 -243 -221 -200 -192 -185 -165 -144
Change (%) -43.42 13.69 12.04 42.27 29.71 5.10 4.85 -5.26 -5.55 -1.71 -1.74 -5.71 -6.06 -8.94 -9.82 -3.63 -3.77 -11.02 -12.38
% of Revenue -3,396.36 -960.82 -1,092.33 -1,223.85 -1,127.32 -1,081.12 -996.82 -930.94 -1,577.46 -7,047.57 -6,154.94 -5,441.40 -8,075.75 -17,810.33 -6,922.26 -9,961.93 -38,362.71 -9,138.25 -16,262.64

Source: Capital IQ

Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista